300819-51-6

Basic information

• Product Name: 5-(3-TRIFLUOROMETHYL-BENZYL)-THIAZOL-2-YLAMINE
• Synonyms: 5-(3-TRIFLUOROMETHYL-BENZYL)-THIAZOL-2-YLAMINE;TIMTEC-BB SBB012022;5-{[3-(trifluoromethyl)phenyl]methyl}-1,3-thiazol-2-amine
• CAS NO: 300819-51-6
• Molecular Formula: C₁₁H₉F₃N₂S
• Molecular Weight: 258.26
• Mol File: 300819-51-6.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-(3-TRIFLUOROMETHYL-BENZYL)-THIAZOL-2-YLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(3-TRIFLUOROMETHYL-BENZYL)-THIAZOL-2-YLAMINE(300819-51-6)
• EPA Substance Registry System: 5-(3-TRIFLUOROMETHYL-BENZYL)-THIAZOL-2-YLAMINE(300819-51-6)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 300819-51-6(Hazardous Substances Data)

Upstream product

• 454-89-7 3-Trifluoromethylbenzaldehyde 
• 1081314-08-0 tert-butyl-{5-[hydroxy(3-trifluoromethylphenyl)methyl]thiazol-2-yl}carbamate 
• 98-16-8 3-trifluoromethylaniline 
• 871543-59-8 3-(3-(trifluoromethyl)phenyl)acrylaldehyde 
• 17356-08-0 thiourea 
• 21172-41-8 3-[3-(trifluoromethyl)phenyl]propanal 
• 807667-31-8 2-chloro-3-(3-trifluoromethyl-phenyl)-propionaldehyde 
• 34648-94-7 m-trifluoromethyldiazonium chloride 

Downstream Products

• 1081314-68-2 C₂₉H₃₄F₃N₃O₄S 
• 1081314-62-6 C₂₇H₃₀F₃N₃O₄S 
• 1081314-73-9 C₂₉H₃₂F₃N₃O₅S 
• 1081314-83-1 C₂₇H₂₈F₃N₃O₅S 
• 1081314-19-3 C₂₇H₂₉F₃N₂O₅S 
• 1081314-36-4 C₂₈H₃₁F₃N₂O₆S 
• 1081314-03-5 C₃₂H₃₇F₃N₂O₇S 
• 1081314-05-7 C₁₁H₇BrF₃NS 
• 1081313-47-4 C₂₅H₂₆F₃N₃O₄S 
• 1295113-34-6 C₂₂H₁₉F₃N₂O₅S 
• 1081313-43-0 C₂₁H₁₉F₃N₂O₄S 
• 892710-47-3 C₁₉H₁₅F₃N₂O₂S 
• 1010282-60-6 C₁₉H₁₅F₃N₂O₂S 
• 304895-80-5 C₂₁H₁₇F₃N₂O₂S 

Relevant articles and documents

Synthesis and BK channel-opening activity of 2-amino-1,3-thiazole derivatives

A series of 2-amino-5-arylmethyl- or 5-heteroarylmethyl-1,3-thiazole derivatives were synthesized and evaluated for BK channel-opening activities in cell-based fluorescence assay and electrophysiological recording. The assay results indicated that the activities of the investigated compounds were influenced by the physicochemical properties of the substituent at benzene ring.

MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF

Formulations and methods for reducing blood glucose and/or increasing insulin signaling in a subject have been developed. The formulations include SBI-477 and compounds based on SBI-477 i.e., SBI-477 analogs (collectively, SBI-477 compounds) and/or Mondo family inhibitors, in an effective amount to inhibit intracellular lipid accumulation and/or increase cellular glucose uptake when compared to levels in a control subject not administered the composition. Also disclosed are methods of reducing intracellular lipid accumulation and/or increase glucose uptake in a subject in need thereof. The method includes administering to the subject an effective amount of SBI-477 compounds and/or Mondo family inhibitor to reducing intracellular lipid accumulation and/or increase glucose uptake in the subject. Also disclosed are method for treating one or more Myc-driven cancers, including neuroblastoma, lung squamous cell carcinoma/lung adenocarcinoma, liver hepatocellular carcinoma, colon adenocarcinoma, acute myeloid leukemia, and breast invasive carcinoma.

Novel and potent inhibitors of stearoyl-CoA desaturase-1. Part I: Discovery of 3-(2-hydroxyethoxy)-4-methoxy-N-[5-(3-trifluoromethylbenzyl)thiazol-2-yl]benzamide

A series of structurally novel stearoyl-CoA desaturase-1 (SCD-1) inhibitors has been identified by optimizing a hit from our corporate library. Preliminary structure-activity relationship (SAR) studies led to the discovery of the highly potent and orally bioavailable thiazole-based SCD-1 inhibitor, 3-(2-hydroxyethoxy)-4-methoxy-N-[5-(3-trifluoromethylbenzyl)thiazol-2-yl]benzamide (23a).